TY - JOUR
T1 - Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study
AU - Naqvi, Kiran
AU - Daver, Naval
AU - Pemmaraju, Naveen
AU - Bose, Prithviraj
AU - Garcia-Manero, Guillermo
AU - Cortes, Jorge
AU - Kantarjian, Hagop M.
AU - Verstovsek, Srdan
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.
AB - Ruxolitinib is the only approved therapy for myelofibrosis (MF). However, its use in patients with myeloproliferative neoplasms (MPN) not participating in clinical studies has been poorly described. We reviewed the medical records of 45 patients (35 MF, 10 others) treated with ruxolitinib at our center, off clinical study, during the year after its approval. Patients had advanced features and were refractory to multiple therapies. Ruxolitinib was effective in reducing splenomegaly (51% response rate) and constitutional symptoms (42% response rate). It controlled blood counts in patients with polycythemia and thrombocythemia but was not effective in patients with non-classic MPNs. Ruxolitinib was an active therapy in patients previously treated with a JAK inhibitor and was safely combined with hypomethylating agents in patients with elevated blasts. Median overall survival was 24 months; 10 patients transformed to acute leukemia. Its use in combination with other active agents should be further explored in clinical studies.
KW - Myelofibrosis
KW - myeloproliferative neoplasms
KW - ruxolitinib
KW - splenomegaly
UR - http://www.scopus.com/inward/record.url?scp=84982786659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982786659&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1217528
DO - 10.1080/10428194.2016.1217528
M3 - Article
C2 - 27494751
AN - SCOPUS:84982786659
SN - 1042-8194
VL - 58
SP - 866
EP - 871
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -